Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 330

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus

Open access
Verweij, Paul E., Ananda-Rajah, Michelle, Andes, David, Arendrup, Maiken C., Brüggemann, Roger J., Chowdhary, Anuradha, Cornely, Oliver A., Denning, David W., Groll, Andreas H., Izumikawa, Koichi, Kullberg, Bart Jan, Lagrou, Katrien, Maertens, Johan, Meis, Jacques F., Newton, Pippa, Page, Iain, Seyedmousavi, Seyedmojtaba, Sheppard, Donald C., Viscoli, Claudio, Warris, Adilia, Donnelly, J. Peter·2015·Drug Resistance Updates

Abstract

An international expert panel was convened to deliberate the management of azole-resistant aspergillosis. In culture-positive cases, in vitro susceptibility testing should always be performed if antifungal therapy is intended. Different patterns of resistance are seen, with multi-azole and pan-azole resistance more common than resistance to a single triazole. In confirmed invasive pulmonary aspergillosis due to an azole-resistant Aspergillus, the experts recommended a switch from voriconazole to liposomal amphotericin B (L-AmB; Ambisome(®)). In regions with environmental resistance rates of ≥10%, a voriconazole-echinocandin combination or L-AmB were favoured as initial therapy. All experts recommended L-AmB as core therapy for central nervous system aspergillosis suspected to be due to an azole-resistant Aspergillus, and considered the addition of a second agent with the majority favouring flucytosine. Intravenous therapy with either micafungin or L-AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary aspergillosis due to a pan-azole-resistant Aspergillus. Local and national surveillance with identification of clinical and environmental resistance patterns, rapid diagnostics, better quality clinical outcome data, and a greater understanding of the factors driving or minimising environmental resistance are areas where research is urgently needed, as well as the development of new oral agents outside the azole drug class.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drup.2015.08.001

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Cited by

See all 330

Metadata

Authors
Verweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., Cornely, O. A., Denning, D. W., Groll, A. H., Izumikawa, K., Kullberg, B. J., Lagrou, K., Maertens, J., Meis, J. F., Newton, P., Page, I., Seyedmousavi, S., Sheppard, D. C., Viscoli, C., Warris, A., & Donnelly, J. P.
Venue
Drug Resistance Updates
Publisher
Elsevier BV
Published
2015-07
Volume
21-22
Pages
30-40
ISSN
1368-7646 (ISSN-L)
OpenAlex
W2114168745
Cited by
330
References
100
FWCI
31.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. https://app.cochat.ai/papers/10.1016/j.drup.2015.08.001
The paper
Verweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., Cornely, O. A., Denning, D. W., Groll, A. H., Izumikawa, K., Kullberg, B. J., Lagrou, K., Maertens, J., Meis, J. F., Newton, P., Page, I., Seyedmousavi, S., Sheppard, D. C., Viscoli, C., . . . Donnelly, J. P. (2015). International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2015.08.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.